Evidence map›Paper›PMID 36653191›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2023

AAV Vector Mediated Delivery of NG2 Function Neutralizing Antibody and Neurotrophin NT-3 Improves Synaptic Transmission, Locomotion, and Urinary Tract Function after Spinal Cord Contusion Injury in Adult Rats.

Hayk A Petrosyan, Valentina Alessi, Kristin Lasek, Sricharan Gumudavelli, Robert Muffaletto, Li Liang, William F Collins, Joel Levine, Victor L Arvanian

Open access · greenAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. NG2 Glia and Cellular Crosstalk in Health and Disease: Focus on Spinal Cord Injury.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hayk A PetrosyanNorthport Veterans Affairs Medical Center, Northport, New York 11768.
Valentina AlessiNorthport Veterans Affairs Medical Center, Northport, New York 11768.
Kristin LasekNorthport Veterans Affairs Medical Center, Northport, New York 11768.
Sricharan GumudavelliDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794.
Robert MuffalettoDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794.
Li LiangNorthport Veterans Affairs Medical Center, Northport, New York 11768.
William F CollinsDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794.
Joel LevineDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794.
Victor L ArvanianNorthport Veterans Affairs Medical Center, Northport, New York 11768 victor.arvanian@gmail.com.
Stony Brook University · USNorthport VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NG2 is a structurally unique transmembrane chondroitin sulfate proteoglycan (CSPG). Its role in damaged spinal cord is dual. NG2 is considered one of key inhibitory factors restricting axonal growth following spinal injury. Additionally, we have recently detected its novel function as a blocker of axonal conduction. Some studies, however, indicate the importance of NG2 presence in the formation of synaptic contacts. We hypothesized that the optimal treatment would be neutralization of inhibitory functions of NG2 without its physical removal. Acute intraspinal injections of anti-NG2 monoclonal antibodies reportedly prevented an acute block of axonal conduction by exogenous NG2. For prolonged delivery of NG2 function neutralizing antibody, we have developed a novel gene therapy: adeno-associated vector (AAV) construct expressing recombinant single-chain variable fragment anti-NG2 antibody (AAV-NG2Ab). We examined effects of AAV-NG2Ab alone or in combination with neurotrophin NT-3 in adult female rats with thoracic T10 contusion injuries. A battery of behavioral tests was used to evaluate locomotor function.

Indexed as

ContusionsSingle-Chain AntibodiesSpinal Cord InjuriesUrinary TractAnimalsChondroitin Sulfate Proteoglycan 4FemaleLocomotionNerve Growth FactorsNeurotrophin 3RatsRecovery of FunctionSpinal CordSynaptic TransmissionChondroitin Sulfate Proteoglycan 4Nerve Growth FactorsNeurotrophin 3Single-Chain AntibodiesBladder FunctionLocomotionNG2ProteoglycanSCITransmission

Identifiers

PMID36653191
PMCPMC10008066
OpenAlexW4317384301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.